Molecule intelOpportunity: Lower0

Dobutamine

17 brands · 17 companies · product forms

2 DRAP alerts

Opportunity snapshot

Launch attractiveness
22
Market saturation
43
Price room
0
Regulatory risk
70
17
brands
17
companies
Rs 4,255.24
median price
2
price points
1x
price spread
65
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 6%

Price room

Across observed sources and strengths
CheapestRs 4,255.24
MedianRs 4,255.24
Most expensiveRs 4,255.24
Spread1×
Sources: DRAP-official

Only 2 trusted price points; variation not scored (low data).

Brands & products on the market

Sample of 1 live product for Dobutamine — each links to its own medicine page.

Regulatory alerts

Recall exposurelatest 2026-04-14
22. Recall Alert – Drug Products declared substandard by Provincial laboratories.
126. Recall Alert (Class-I) – Injection Cara-Doba 5ml – Substandard

Why this score

Launch attractiveness

40% supply-gap(20) + 25% price-variation(0) + 20% low-competition(57) + 15% supply-disruption(40), damped by confidence(65). Higher = more attractive, less crowded opportunity.

Market saturation

17 canonical companies and 17 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

Only 2 trusted price points; variation not scored (low data).

Regulatory risk

2 DRAP alert(s), latest 2026-04-14 incl. recall/safety.

Confidence

Reduced by: sparse price data, no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.